ABL Bio Inc
KOSDAQ:298380
ABL Bio Inc
PP&E Net
ABL Bio Inc
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
A
|
ABL Bio Inc
KOSDAQ:298380
|
PP&E Net
â‚©85.4B
|
CAGR 3-Years
196%
|
CAGR 5-Years
76%
|
CAGR 10-Years
N/A
|
|
![]() |
Celltrion Inc
KRX:068270
|
PP&E Net
â‚©1.2T
|
CAGR 3-Years
9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
![]() |
SK Bioscience Co Ltd
KRX:302440
|
PP&E Net
â‚©982.6B
|
CAGR 3-Years
64%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
PP&E Net
â‚©151B
|
CAGR 3-Years
16%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
PP&E Net
â‚©147.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
![]() |
Alteogen Inc
KOSDAQ:196170
|
PP&E Net
â‚©19.6B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
0%
|
CAGR 10-Years
45%
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's PP&E Net?
PP&E Net
85.4B
KRW
Based on the financial report for Dec 31, 2024, ABL Bio Inc's PP&E Net amounts to 85.4B KRW.
What is ABL Bio Inc's PP&E Net growth rate?
PP&E Net CAGR 5Y
76%
Over the last year, the PP&E Net growth was 12%. The average annual PP&E Net growth rates for ABL Bio Inc have been 196% over the past three years , 76% over the past five years .